Literature DB >> 6184557

Clinical and pharmacological properties of calcium antagonists in essential hypertension in humans and spontaneously hypertensive rats.

K Aoki, Y Kawaguchi, K Sato, S Kondo, M Yamamoto.   

Abstract

The abnormal cellular contractile mechanisms causing the development of essential hypertension in humans and rats were investigated, primarily with the use of Ca2+ and Ca antagonists. Helical strips isolated from mesenteric arteries of spontaneously hypertensive rats (Aoki SHR) showed an increased Ca2+ -induced tension development in the presence of noradrenaline or a high potassium concentration. The tension development of the SHR strips was greatly inhibited by Ca antagonists. In the patients with essential hypertension, both elevated blood pressure and elevated total peripheral resistance were reduced to normal levels by Ca antagonists. The drugs increased cardiac output and stroke volume. The hypotensive effect of the drugs was due to arterial vasodilation. We concluded that there might be an abnormally high sensitivity of the cell membrane system of vascular smooth muscle to both Ca2+ and Ca antagonists in patients with essential hypertension and in SHR. Abnormalities in Ca2+ channels, Ca2+ uptake, and Ca2+ binding of the cell membrane, which cause the high sensitivity, might greatly increase the Ca2+ levels of cytosol in the muscle. The increased cytosol Ca2+ induces, in turn, either increased contraction or decreased relaxation and a decrease in the arterial lumen. Any decrease in the lumen results in peripheral resistance enhancement, which is responsible for the increase in arterial blood pressure in essential hypertension. Thus, we propose the membrane theory of essential hypertension--that membrane abnormalities lead to hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6184557

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  The antihypertensive effect of arginine.

Authors:  Sudesh Vasdev; Vicki Gill
Journal:  Int J Angiol       Date:  2008

2.  Role of methylglyoxal in essential hypertension.

Authors:  Sudesh Vasdev; Jennifer Stuckless
Journal:  Int J Angiol       Date:  2010

3.  Intracranial effects of nicardipine.

Authors:  M R Gaab; T Czech; A Korn
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

4.  Nicardipine HCl: clinical experience in patients undergoing anaesthesia for intracranial aneurysm clipping.

Authors:  D S Warner; M D Sokoll; M Maktabi; J C Godersky; H P Adams
Journal:  Can J Anaesth       Date:  1989-03       Impact factor: 5.063

Review 5.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

6.  Cardiovascular effects of substituted tetrahydroisoquinolines in rats.

Authors:  H Dong; C M Lee; W L Huang; S X Peng
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

7.  Hypotensive effects of diltiazem to normals and essential hypertensives.

Authors:  K Aoki; K Sato; S Kondo; M Yamamoto
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 8.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

9.  In vitro vascular effects of cicletanine in pregnancy-induced hypertension.

Authors:  A B Ebeigbe; M Cabanie
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.